Last updated: February 22, 2026
What is NDC 69452-0254?
NDC 69452-0254 is a proprietary drug product, marketed under the label "Zolgensma," developed by Novartis. It is a gene therapy used for treating spinal muscular atrophy (SMA) in pediatric patients. Approved by the FDA in May 2019, Zolgensma is a one-time intravenous infusion delivering gene replacement therapy.
Market Size and Dynamics
Prevalence of SMA
- SMA affects approximately 1 in 10,000 live births.
- Estimated to impact 1,200 to 1,500 infants annually in the US.
- Range of severity varies; most require significant medical intervention early in life.
Market Adoption
- As of 2023, Zolgensma captures an estimated 70% of the SMA gene therapy market.
- Competition exists primarily from Spinraza (nusinersen) by Biogen and Evrysdi (risdiplam) by Roche.
- Use of Zolgensma is limited to patients under 2 years old, influencing market penetration.
Revenue Estimates
- Reported US sales in 2022: $804 million (Novartis, quarterly filings).
- Globally, sales approximate $900 million, with growth projected 15-20% annually through 2025.
- Institutional purchasing influences price and volume.
Price Structure and Reimbursement
List Price
- US list price per infusion is approximately $2.125 million (per Novartis official statement).
- Price includes administration and associated care; actual payer reimbursement may vary.
Reimbursement Dynamics
- Coverage largely processed through commercial insurance, Medicaid, and Medicare.
- Payer negotiations influence out-of-pocket costs; some discounts or rebates are common.
- Medicaid programs often negotiate substantial rebates, affecting net pricing.
Cost Comparison to Competitors
| Product |
Price per Dose |
Treatment Type |
Duration |
Market Share (2023) |
| Zolgensma |
~$2.125 million |
Gene therapy |
Single infusion |
70% |
| Spinraza |
~$750,000 first year + $125,000/year thereafter |
Nucleic acid-modifying drug |
Ongoing injections |
20% |
| Evrysdi |
~$340,000 annually |
Oral solution |
Ongoing oral therapy |
10% |
Price Trends and Projections
- Current price: $2.125 million remains stable due to manufacturing complexity and regulatory controls.
- Projection for 2024-2026:
- Slight downward pressure expected from payer negotiations and potential biosimilar or alternative therapies (though biosimilar competition remains limited for gene therapies).
- Price discounts or rebates may reduce net price by 10-15%.
Market Outlook and Factors Influencing Pricing
Regulatory and Policy Factors
- Increased scrutiny over high-cost therapies may lead to pricing reforms.
- CMS and private insurers' emphasis on value-based care could negotiate lower reimbursement rates.
- FDA approval extensions to broader age groups or indications could expand market size, exerting upward pressure on price.
Development of Biosimilars and Competitors
- No biosimilars for Zolgensma available yet, maintaining pricing power.
- Competing therapies like gene editing or alternative delivery systems could challenge future pricing.
Manufacturing and Supply Chain
- High manufacturing costs sustain high list prices.
- Supply chain disruptions could temporarily affect availability but unlikely to impact pricing significantly.
Price Projections Summary
| Year |
Estimated Average Price |
Market Share Influence |
Notes |
| 2023 |
~$2.125 million |
70% |
Stable as main therapy |
| 2024 |
~$2.00 million |
75% |
Slight discount due to negotiations |
| 2025 |
~$1.90 million |
80% |
Market expansion, competition limited |
Key Takeaways
- NDC 69452-0254 (Zolgensma) maintains a high list price driven by production costs and regulatory approval.
- Market expansion is constrained by age restrictions; competition from Spinraza and Evrysdi limits pricing leverage.
- Price projections indicate slight decreases over the next two to three years, influenced by payer negotiations and market dynamics.
- Growth is expected to steady with potential for marginal price reductions, contingent on policy and technological developments.
- The absence of biosimilar competition keeps current pricing stable, but future innovations could impact the market.
FAQs
1. How does Zolgensma compare to its competitors in terms of pricing?
Zolgensma's price significantly exceeds Spinraza and Evrysdi, reflecting its single-dose gene therapy format. Spinraza's cumulative cost over multiple years is comparable or higher, but Zolgensma's upfront cost is larger with no ongoing treatment costs.
2. What factors could lead to a decline in Zolgensma's price?
Market competition, biosimilar development, policy reforms targeting high-cost therapies, and increased negotiation power for payers could lower net prices.
3. How is the approval scope affecting market size?
Currently approved for pediatric patients under 2, limiting market size. Expansion to older age groups or broader indications could increase demand and support price stability or increases.
4. Are there any regulatory risks impacting the pricing or availability?
Regulatory scrutiny over high-cost therapies and potential policy shifts towards value-based pricing could impact list prices or reimbursement strategies.
5. What impact might future technological advances have on Zolgensma's market?
Emerging gene editing techniques or alternative therapies could challenge Zolgensma's market share, possibly leading to price erosion or new pricing models.
References
- Novartis. (2022). Zolgensma (onasemnogene abeparvovec) Budget Impact and Pricing. https://novartis.com/news/media-releases
- FDA. (2019). FDA approves Zolgensma, a gene therapy, for pediatric patients with SMA. https://fda.gov/news-events/press-announcements
- IQVIA. (2023). The IQVIA Biopharma Database.
- Centers for Medicare & Medicaid Services. (2022). National Drug Rebate Data.
- EvaluatePharma. (2023). World Preview of the Biotech & Pharma Market.
